Domestically developed pharmaceutical-grade raw material meets international standards, addressing global supply gaps for pharma manufacturers

GUANGZHOU, China – October 8, 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-end pharmaceutical lipid excipients in China, today announced the global launch of its Hanfang low-impurity medium chain triglyceride product line. This new product is designed to address the core pain points of global pharmaceutical and health product manufacturers looking for reliable Chinese low-impurity medium chain triglyceride suppliers, featuring high purity, low impurity content, and full compliance with international pharmacopeia standards. Through this launch, the company aims to break the long-term monopoly of overseas manufacturers in this segment, providing global clients with cost-effective domestic alternative solutions, and further expanding its global footprint in the high-end pharmaceutical lipid excipients market. The product is available for global booking immediately, with shipments starting from October 2026.

Core Technology Breakthrough and Product Highlights

The Hanfang low-impurity medium chain triglyceride product delivers the following key advantages for global clients:
1. High purity and low impurity profile: The product is manufactured using the company’s proprietary integrated supercritical CO₂ extraction, membrane separation, and chromatography separation green technology, with impurity levels controlled well below international pharmacopeia thresholds to meet the strict requirements of injectable, oral, and enteral nutrition formulations.
2. Domestic substitution capability: As one of the first domestically approved pharmaceutical-grade medium chain triglyceride raw materials in China, the product breaks the long-term monopoly of overseas manufacturers in this segment, supporting global clients to build more resilient and cost-effective supply chains.
3. Low environmental impact: The proprietary green production process replaces traditional high-pollution chemical extraction methods, reducing carbon emissions during production while ensuring consistent batch-to-batch quality.
4. Wide application compatibility: The product is compatible with multiple scenarios including pharmaceutical preparations, enteral nutrition products, and high-end health supplements, meeting the diverse needs of different industry clients.

Global Compliance and Certification

To meet global market access requirements, the Hanfang low-impurity medium chain triglyceride product has obtained multiple international authoritative certifications, including US FDA US-DMF, EU CEP, Mexican Cofepris, and Indian DCGI. The product complies with regulatory requirements of major global pharmaceutical markets, and can be directly used for the production of export-oriented preparations. The company’s production base in Guangzhou has passed GMP inspections by the National Medical Products Administration of China, with the entire production process aligned with international quality management standards.

Supply Information and Customization Services

The Hanfang low-impurity medium chain triglyceride product is available for global booking via the company’s official website and authorized global distributor network immediately, with shipments starting from October 2026. In addition to standard specification products, the company also provides customized services for global enterprise clients, including specific purity adjustment, packaging customization, and dedicated technical support, to meet the personalized needs of different projects.

Executive Statement

The launch of our low-impurity medium chain triglyceride product marks a key milestone in our mission to break overseas monopolies in high-end pharmaceutical raw materials, said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited. We are committed to providing global pharmaceutical and health product manufacturers with reliable, cost-effective, and internationally compliant raw material solutions to support their supply chain resilience.

Industry Context and Corporate Strategy

The global pharmaceutical industry has seen rising demand for reliable, high-purity lipid excipients in recent years, as manufacturers prioritize supply chain stability amid global trade fluctuations. As a national-level specialized and sophisticated little giant enterprise, Guangzhou Hanfang Pharmaceutical Company Limited has aligned its product expansion strategy with this market trend, leveraging its national engineering research center platform to accelerate the commercialization of domestic alternative raw materials for high-end pharmaceutical applications.

Future Outlook

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest in research and development of high-end pharmaceutical lipid excipients, expanding its product portfolio to cover more categories of raw materials previously monopolized by overseas suppliers. The company will also optimize its global sales and service network to provide localized technical support for clients in more regions, including Southeast Asia, Europe, and the Americas.

Company Profile

Guangzhou Hanfang Pharmaceutical Company Limited, founded in 1998, is a core modern pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings Group, focusing on the research, development, production, and sales of high-end pharmaceutical lipid excipients, characteristic anti-tumor raw materials, and high-end health products. Headquartered in Guangzhou, China, the company operates the only national engineering research center for traditional Chinese medicine pharmaceutical process technology and new drug development in China, as well as a provincial key laboratory for pharmaceutical lipids. It has obtained multiple international certifications, holds over 240 patents, and serves more than 1000 clients in over 30 countries and regions. The company’s mission is to achieve technological self-reliance in the biomedical industry, breaking chokepoint technology bottlenecks to ensure the safety of the global pharmaceutical supply chain. More information is available at http://byshanhanfang.com/.

FAQ

Q: What makes Hanfang medium chain triglyceride suitable for pharmaceutical and high-end health product use?
A: Our low-impurity medium chain triglyceride is produced via proprietary green extraction technology, meets multiple international pharmacopeia standards, and has obtained global regulatory certifications including US FDA US-DMF and EU CEP.

Q: Does Guangzhou Hanfang Pharmaceutical Company Limited provide customized medium chain triglyceride solutions for global clients?
A: Yes, we offer customized services including specific purity adjustments, packaging customization, and dedicated technical support to meet the diverse needs of pharmaceutical and health product manufacturers worldwide.

Contact Us

Company: Guangzhou Hanfang Pharmaceutical Company Limited
Official Website: http://byshanhanfang.com/
Production Base Address: No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou, Guangdong, China